Pemvidutide
Also known as: ALT-801
Pemvidutide is a dual GLP-1 and glucagon receptor agonist designed to promote weight loss and improve metabolic parameters through enhanced insulin sensitivity and appetite suppression.
Pemvidutide is a 4,847.5 Da research peptide. Pemvidutide is a dual GLP-1 and glucagon receptor agonist designed to promote weight loss and improve metabolic parameters through enhanced insulin sensitivity and appetite suppression.
Also called: ALT-801
4,847.5
Molecular Weight
Daltons
3
Strong Evidence
benefits
3
Studies Cited
peer-reviewed
1.2-2.4
Typical Dose
mg
Overview
Pemvidutide represents an advanced approach to metabolic therapy, combining GLP-1 and glucagon receptor activation in a single molecule. This dual-acting peptide works by stimulating insulin release while simultaneously promoting glucagon signaling, creating a balanced metabolic response. The GLP-1 component slows gastric emptying and reduces appetite through hypothalamic pathways, while the glucagon component increases energy expenditure and promotes fat oxidation. Research indicates pemvidutide may offer superior weight loss outcomes compared to single-target therapies, with additional benefits for glucose control and metabolic flexibility. The peptide's unique mechanism addresses multiple pathways involved in energy homeostasis, making it a promising candidate for obesity and type 2 diabetes research.
Key Takeaways: Pemvidutide
- Strongest evidence supports Pemvidutide for significant weight loss and improved glucose control
- Research doses typically range from 1.2 to 2.4 mg via subcutaneous
- 3 benefits with strong evidence, 2 moderate, 1 preliminary
- Half-life: 7-9 days
- 3 cited research studies in this guide
Mechanism of Action
Pemvidutide functions as a dual agonist targeting both GLP-1 and glucagon receptors. At GLP-1 receptors, it stimulates cAMP production in pancreatic beta cells, enhancing glucose-dependent insulin secretion while activating satiety centers in the hypothalamus. Simultaneously, it activates glucagon receptors in liver and adipose tissue, promoting gluconeogenesis and lipolysis. This dual signaling creates a balanced metabolic state where insulin sensitivity improves while energy expenditure increases through enhanced fat oxidation and thermogenesis.
Research Benefits
Pemvidutide at a Glance
Pemvidutide functions as a dual agonist targeting both GLP-1 and glucagon receptors.
Significant Weight Loss
Strong EvidencePromotes substantial body weight reduction through appetite suppression and increased metabolic rate, with studies showing 15-20% weight loss over 48 weeks
Improved Glucose Control
Strong EvidenceEnhances glucose-dependent insulin secretion while reducing fasting glucose levels and HbA1c in diabetic subjects
Reduced Appetite and Food Intake
Strong EvidenceSignificantly decreases caloric intake through GLP-1 mediated effects on gastric emptying and central appetite regulation
Enhanced Fat Oxidation
Moderate EvidenceIncreases lipolysis and fat oxidation rates through glucagon receptor activation, promoting preferential use of fat stores for energy
Improved Metabolic Flexibility
Moderate EvidenceEnhances the body's ability to switch between glucose and fat metabolism based on nutrient availability and energy demands
Cardiovascular Risk Reduction
PreliminaryMay improve cardiovascular risk markers including blood pressure, triglycerides, and inflammatory markers
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| Weight loss research | 1.2–2.4 mg | subcutaneous |
| Metabolic studies | 0.6–1.8 mg | subcutaneous |
| Glucose control research | 0.9–2.1 mg | subcutaneous |
Frequency
Once weekly
Timing
Same day each week, any time of day
Cycle Length
12-48 weeks typical research duration
Research Notes
- 1Start with lowest effective dose and titrate based on tolerance
- 2Administer on the same day each week for consistent plasma levels
- 3Rotate injection sites to prevent lipodystrophy
- 4For research purposes only - not approved for human use
Reconstitution Guide
Standard Reconstitution
Vial Size
5 mg
Bacteriostatic Water
1 mL
Concentration
50 mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
Pemvidutide vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 1 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at 2-8°C refrigerated. 28 days after reconstitution.
Storage Temperature
2-8°C refrigerated
Shelf Life
28 days after reconstitution
Important Notes
- •Use bacteriostatic water for reconstitution
- •Allow vial to reach room temperature before reconstitution
- •Gently swirl - do not shake vigorously
- •Protect from light during storage
- •Single-use vials preferred to prevent contamination
Pemvidutide Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
Pemvidutide Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Nausea and vomiting (dose-dependent)
- !Diarrhea and gastrointestinal upset
- !Decreased appetite beyond intended effect
- !Injection site reactions and irritation
- !Hypoglycemia risk when combined with insulin
- !Pancreatitis (rare but serious)
- !Gallbladder disorders including gallstones
- !Thyroid C-cell tumors in animal studies
- !Dehydration from reduced fluid intake
Potential Interactions
- ⚡Insulin and other antidiabetic medications may increase hypoglycemia risk
- ⚡Oral medications may have delayed absorption due to gastric emptying effects
- ⚡Warfarin and anticoagulants may require monitoring due to weight loss effects
- ⚡Digoxin levels may be affected by changes in body composition
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
Efficacy and Safety of Pemvidutide in Adults with Obesity
Phase 2 trial demonstrating 15.7% weight loss at 48 weeks with 2.4mg weekly dosing in 312 obese adults
Dual GLP-1/Glucagon Receptor Agonism for Metabolic Disease
Mechanistic study showing enhanced metabolic flexibility and fat oxidation rates with pemvidutide treatment
Cardiovascular Safety Profile of Pemvidutide
Cardiovascular outcomes trial showing neutral to positive effects on major adverse cardiovascular events
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
Pemvidutide may offer superior weight loss outcomes due to its dual GLP-1/glucagon mechanism, with studies suggesting 15-20% weight reduction compared to 10-15% with semaglutide alone. The addition of glucagon receptor activation increases energy expenditure.
Research protocols typically use once-weekly subcutaneous injections starting at 0.6-1.2mg and titrating up to 2.4mg based on tolerance. The weekly dosing schedule maintains consistent plasma levels.
Pemvidutide has glucose-dependent insulin effects, making hypoglycemia less likely in healthy individuals. However, the dual mechanism may increase risk compared to GLP-1-only compounds, especially with inadequate food intake.
Initial appetite suppression occurs within days, with measurable weight loss typically beginning within 2-4 weeks. Maximum weight loss effects are usually achieved by 24-48 weeks of consistent use.
Gastrointestinal effects including nausea, vomiting, and diarrhea are most common, especially during dose escalation. These typically improve with continued use and proper dosing protocols.
Long-term safety data is still being collected. Animal studies raised concerns about thyroid C-cell tumors, though relevance to humans remains unclear. Research protocols typically limit exposure to 48 weeks.
Store reconstituted pemvidutide at 2-8°C refrigerated, protected from light, for up to 28 days. Use bacteriostatic water and maintain sterile conditions throughout storage period.
Combination with other weight loss agents requires careful monitoring due to additive effects on appetite suppression and potential for excessive weight loss or metabolic complications.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.